ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $318,400.00 in Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction on Monday, May 6th. The shares were sold at an average price of $15.92, for a total transaction of $318,400.00. Following the completion of the sale, the insider now owns 604,205 shares of the company’s stock, valued at approximately $9,618,943.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jaume Pons also recently made the following trade(s):

• On Tuesday, April 16th, Jaume Pons sold 50,000 shares of ALX Oncology stock. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00.
• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The shares were sold at an average price of $11.15, for a total value of $223,000.00.

ALX Oncology Stock Performance

Shares of ALXO stock traded down $0.95 during trading on Wednesday, hitting $16.61. The company’s stock had a trading volume of 471,166 shares, compared to its average volume of 459,636. The business has a fifty day moving average of $13.70 and a 200-day moving average of $12.72. The company has a market cap of $830.50 million, a PE ratio of -4.43 and a beta of 1.30. ALX Oncology Holdings Inc. has a 52 week low of $3.94 and a 52 week high of $17.83. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). As a group, research analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALXO has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ALX Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ALX Oncology in the fourth quarter valued at approximately $28,000. SG Americas Securities LLC bought a new position in shares of ALX Oncology during the 3rd quarter worth $48,000. Forefront Analytics LLC purchased a new stake in ALX Oncology in the 3rd quarter worth about $66,000. China Universal Asset Management Co. Ltd. raised its stake in ALX Oncology by 445.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after acquiring an additional 4,706 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new stake in ALX Oncology during the third quarter valued at about $96,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.